A unique approach for discovering new autophagy therapeutics
The Lysoseeker™ Platform
An unbiased, data-driven approach to discover new biology.
Lysoseeker™ is a set of capabilities which goes from screen to drug via new mechanisms and disease utility.
We start with an unbiased phenotypic screen and use proprietary technologies to understand the mechanisms and targets of the autophagy-inducing molecules we identify.
We also screen these new molecules in a variety of translatable cellular models of disease.
With Lysoseeker™ we have discovered several highly promising lead molecules which are being optimised towards the clinic and restore autophagy in vivo via completely novel biology.
The process of autophagy features multiple steps and is highly dynamic.
We are building an understanding of these processes at a transcriptional and proteomic level and probing them with molecules to discover new intervention points, with the goal of boosting the whole process.
Our unbiased approach is leading to numerous opportunities for intervention.
Michael Schlossmacher, Susan Perlman, Ed Tate and Christian Behl to help advance development of neurodegeneration and rare genetic disease therapeutics
We’re pleased to report that we’ve further strengthened our team in Oxford.
There is a desperate need for novel therapies that can prevent the progressive neurodegeneration in debilitating diseases of ageing, such as Alzheimer’s, Parkinson’s and Huntington’s Disease.
It’s a busy time for Samsara Therapeutics as we move into our new purpose-built labs and offices in the Wood Centre for Innovation in Oxford.